<DOC>
	<DOCNO>NCT02117297</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation follow target immune therapy Gemtuzumab Ozogamicin ( Mylotarg ) give patient average risk AML MDS .</brief_summary>
	<brief_title>SCT Plus Immune Therapy Average Risk AML/MDS</brief_title>
	<detailed_description>Reduced intensity condition regimen Busulfan ( Bu ) Fludarabine ( Flu ) + Anti-Thymocyte Globulin ( ATG ) ( unrelated donor ) reduce toxicity condition regimen Bu/Flu/alemtuzumab , reduce hepatic toxicity regimen melphan/Flu/alemtuzumab AlloSCT , follow Gemtuzumab Ozogamicin consolidation patient average risk AML/MDS meeting eligibility criterion .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Disease Status : AML 1st CR match family donor AML 1st CR unrelated donor AML 2nd CR CRP MDS &lt; = 5 % bone marrow myeloblasts diagnosis Disease Immunophenotype : Disease must express minimum &gt; = 10 % CD33 positivity patient AML Organ Function : Adequate renal function , adequate liver function , adequate cardiac function , adequate pulmonary function Patients active CNS AML disease time preparative regimen Secondary MDS Poor cytogenetics Female patient pregnant Karnofsky &lt; 70 % Lansky &lt; 50 % 10 year less Age &gt; 30 year Seropositive HIV</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>